102460 Stock Chart & Stats
₩9720.00
-₩10.00(-0.10%)
―
--
Day’s Range― - ―
52-Week Range₩9,100.00 - ₩13,200.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)21.87K
Market Cap
₩178.27B
Enterprise Value₩396.16B
Total Cash (Recent Filing)₩7.04B
Total Debt (Recent Filing)₩216.85B
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.41%
Share Statistics
EPS (TTM)-1868.60
Shares Outstanding18,586,811
10 Day Avg. Volume29,438
30 Day Avg. Volume21,869
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)1.37
P/FCF Ratio-29.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Pharmaceutical Business ModelReyon spans research, development, manufacturing, and commercialization, giving it an integrated pharmaceutical operating model. This breadth can support control over product development and commercialization and provides multiple avenues for rebuilding revenue over the medium term.
Meaningful Equity BaseA sizeable equity base provides a more substantial loss-absorption buffer than an extremely thinly capitalized structure. Although leverage has increased, the existing capital foundation may help Reyon continue operating and pursue recovery while managing business volatility.
Positive Current Cash GenerationCurrent operating cash flow and slightly positive free cash flow show that the business is still generating some internal liquidity despite reported losses. If maintained, this provides a base for essential investment and reduces, though does not eliminate, funding pressure.
Bears Say
Sharp Profitability DeteriorationThe shift from earlier modest profitability to large losses represents a material deterioration in earnings power. Deeply negative operating and net margins can consume capital, restrict reinvestment, and make a sustained recovery dependent on substantial operational improvement.
Weak Debt Coverage And Rising LeverageHigher leverage alongside very limited operating-cash-flow coverage reduces financial flexibility and leaves little internally generated capacity to delever. This can constrain investment choices and increase dependence on refinancing or external capital during weak operating periods.
Convertible Financing And Dilution RiskThe lower conversion price makes conversion more attractive to bondholders and increases the potential number of shares issued. Repeated equity-linked financing can therefore weaken existing shareholders’ ownership and signal that liquidity needs may persist.
Reyon Pharmaceutical Co., Ltd. News
102460 FAQ
What was Reyon Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Reyon Pharmaceutical Co., Ltd. lowest stock price was ₩9100.00 and its highest was ₩13200.00 in the past 12 months.
What is Reyon Pharmaceutical Co., Ltd.’s market cap?
Reyon Pharmaceutical Co., Ltd.’s market cap is ₩178.27B.
When is Reyon Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Reyon Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 15 days.
How were Reyon Pharmaceutical Co., Ltd.’s earnings last quarter?
Reyon Pharmaceutical Co., Ltd. released its earnings results on Aug 14, 2026. The company reported -₩370.992 earnings per share for the quarter.
Is Reyon Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Reyon Pharmaceutical Co., Ltd.’s price is currently Undervalued.
Does Reyon Pharmaceutical Co., Ltd. pay dividends?
Reyon Pharmaceutical Co., Ltd. pays a Annually dividend of ₩177 which represents an annual dividend yield of 1.41%. See more information on Reyon Pharmaceutical Co., Ltd. dividends here
What is Reyon Pharmaceutical Co., Ltd.’s EPS estimate?
Reyon Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Reyon Pharmaceutical Co., Ltd. have?
Reyon Pharmaceutical Co., Ltd. has 18,586,811 shares outstanding.
What happened to Reyon Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Reyon Pharmaceutical Co., Ltd. reported an EPS of -₩370.992 in its last earnings report. Following the earnings report the stock price went up 0.298%.
Which hedge fund is a major shareholder of Reyon Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in KR:102460
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Reyon Pharmaceutical Co., Ltd.
Operating both domestically in South Korea and across international markets, REYON Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's diverse range of offerings addresses various therapeutic areas, including adrenal corticosteroids; angiotensin II receptor antagonists; anticholinergics; antiemetics; antihypertensives; anti-inflammatory enzymes; lipid-lowering, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer treatments; antispasmodics; benign prostatic hypertrophy therapies; cough and cold remedies; cardiac stimulants; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis medications; local anesthetics; migraine drugs; a variety of cardiovascular system drugs; medications for neuromuscular disorders; nootropics and neurotonics; non-steroidal anti-inflammatory drugs (NSAIDs); respiratory stimulants; skeletal muscle relaxants; and vasodilators. Established in 1955, REYON Pharmaceutical Co., Ltd. maintains its corporate headquarters in Seoul, South Korea.
Technical Analysis
Chong Kun Dang Holdings Co., Ltd.
―
Daewon Pharmaceutical Co., Ltd
―
YUNGJIN PHARM. CO. LTD
―
Hyundai Pharmaceutical Co., Ltd.
―
Samjin Pharmaceutical Co., Ltd.
―